AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Our FOCUS is the cultural framework for our company. It describes who we are and what we strive for, why we exist, how we work and what we want to achieve.
New initiative elevates the importance of CKD testing
Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.